Metagenomi Inc
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
(a)
Financial Statements. The financial statements of Metagenomi Technologies, LLC and the report of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm, are included in a separate section of this Annual Report on Form 10-K beginning on page F-1. All financial statement schedules are omitted because the information is inapplicable or presented in the notes to the financial statements.
(b)
Exhibits. The following is a list of exhibits filed as part of this Annual Report on Form 10-K:
| ExhibitNumber | Description | Registrant’sForm | Date Filedwith theSEC | ExhibitNumber |
|---|---|---|---|---|
| 2.1+** | Agreement and Plan of Merger by and between Metagenomi Technologies, LLC and Metagenomi, Inc., dated January 24, 2024 | S-1 | 02/07/2024 | 2.1 |
| 3.1** | Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect | 8-K | 02/13/2024 | 3.1 |
| 3.3** | Amended and Restated Bylaws, as currently in effect | 8-K | 02/13/2024 | 3.2 |
| 4.1+** | Registration Rights Agreement among the Registrant and certain of its stockholders, dated January 24, 2024 | S-1 | 02/07/2024 | 4.1 |
| 4.2** | Form of Common Stock Certificate | S-1 | 02/07/2024 | 4.2 |
| 4.3* | Description of Securities of Registrant | * | ||
| 10.1#** | 2024 Stock Option and Incentive Plan and forms of award agreements thereunder | S-1 | 02/07/2024 | 10.2 |
| 10.2#** | 2024 Employee Stock Purchase Plan | S-1 | 02/07/2024 | 10.3 |
| 10.3#** | Form of Officer Indemnification Agreement | S-1 | 02/07/2024 | 10.4 |
| 10.4#** | Form of Director Indemnification Agreement | S-1 | 02/07/2024 | 10.5 |
| 10.5†** | Strategic Collaboration and License Agreement by and between the Registrant and ModernaTX, Inc., dated October 29, 2021 | S-1 | 02/07/2024 | 10.6 |
| 10.6†** | Collaboration and License Agreement by and between the Registrant and Ionis Pharmaceuticals, Inc., dated November 10, 2022 | S-1 | 02/07/2024 | 10.7 |
| 10.7†+** | Development, Option and License Agreement by and between the Registrant and Affini-T Therapeutics, Inc., dated June 14, 2022 | S-1 | 02/07/2024 | 10.8 |
| 10.8** | Lease Agreement between EPL Halleck Investors LLC and Metagenomi, Inc., dated January 22, 2021 | S-1 | 02/07/2024 | 10.9 |
| 10.9* | Sublease Agreement between Dynavax Technologies Corporation and Metagenomi, Inc., dated March 7, 2024 | * | ||
| 10.10** | Lease Agreement between Park Avenue Building LLC and Metagenomi, Inc., dated September 29, 2021 | S-1 | 02/07/2024 | 10.11 |
| 10.11#** | Employment Agreement between the Registrant and Brian C. Thomas, dated as of March 20, 2023 | S-1 | 02/07/2024 | 10.12 |
| 10.12#** | Offer of Employment between the Registrant and Jian Irish, dated as of January 19, 2021 | S-1 | 02/07/2024 | 10.13 |
| 10.13#** | Offer of Employment between the Registrant and Sarah Noonberg, dated as of January 30, 2023 | S-1 | 02/07/2024 | 10.14 |
| ExhibitNumber | Description | Registrant’sForm | Date Filedwith theSEC | ExhibitNumber |
|---|---|---|---|---|
| 10.14#** | Form of Confidentiality and Invention Assignment Agreement | S-1 | 02/07/2024 | 10.15 |
| 10.15#** | Manager Offer Letter between the Registrant and Willard Dere, dated as of August 19, 2021 | S-1 | 02/07/2024 | 10.16 |
| 21.1** | Subsidiaries of the Registrant | S-1 | 02/07/2024 | 21.1 |
| 23.1* | Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm | * | ||
| 24.1* | Power of Attorney (included on signature page) | |||
| 31.1 | Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | * | ||
| 31.2 | Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | * | ||
| 32.1 | Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | * | ||
| 97.1 | Metagenomi, Inc. Compensation Recovery Policy | * | ||
- Filed herewith
** Previously filed
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.